Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019
Simon D., Wollenberg A., Renz H., Simon Kh.
International Archives of Allergy and Immunology
Vol.178, Issue3, P. 207-218
Опубликовано: 2019
Тип ресурса: Статья
Аннотация:
Atopic dermatitis (AD) is a chronic inflammatory skin disease presenting with recurrent eczematous lesions and intense pruritus. It is common and affects both children and adults, often beginning in infancy. Due to the unpredictable disease course, its visible skin lesions, itching and scratching followed by sleeplessness, other associated atopic diseases, and behavioral and psychiatric disorders, AD is an immense burden for patients and caregivers. AD is determined by a genetic predisposition characterized by an impaired skin barrier and a T-helper-2-predominant inflammation. Restoration of the skin barrier is the main approach for treating and preventing AD. In order to cope with acute flares, usually topical corticosteroids (TCS) are applied, while topical calcineurin inhibitors (TCI) are used mainly for maintenance therapy. There is a small group of patients who are refractory to TCS and TCI and require systemic immunosuppressive drugs such as ciclosporin. Novel, targeted therapies
Ключевые слова:
Anti-inflammatory therapy; Atopic dermatitis; Comorbidities; Epithelial barrier; T-helper-2 inflammation
antiinflammatory agent; Janus kinase inhibitor; monoclonal antibody; interleukin 13 receptor; interleukin 4 receptor; Article; atopic dermatitis; atopy; clinical feature; comorbidity; disease burden; disease course; food allergy; heredity; human; inflammation; molecularly targeted therapy; pathogenesis; phenotype; prevalence; priority journal; pruritus; skin barrier dysfunction; skin disease; skin function; Staphylococcus aureus; Th2 cell; antagonists and inhibitors; atopic dermatitis; immunology; Anti-Inflammatory Agents; Comorbidity; Dermatitis, Atopic; Humans; Receptors, Interleukin-13; Receptors, Interleukin-4
Язык текста: Английский
ISSN: 1423-0097
Simon D.
Wollenberg A.
Renz H.
Simon Kh. Khans-Uve 1958-
Симон Д.
Wолленберг А.
Ренз Х.
Симон Х. Ханс-Уве 1958-
Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019
Текст визуальный непосредственный
International Archives of Allergy and Immunology
S. Karger AG
Vol.178, Issue3 P. 207-218
2019
Статья
Anti-inflammatory therapy Atopic dermatitis Comorbidities Epithelial barrier T-helper-2 inflammation
antiinflammatory agent Janus kinase inhibitor monoclonal antibody interleukin 13 receptor interleukin 4 receptor Article atopic dermatitis atopy clinical feature comorbidity disease burden disease course food allergy heredity human inflammation molecularly targeted therapy pathogenesis phenotype prevalence priority journal pruritus skin barrier dysfunction skin disease skin function Staphylococcus aureus Th2 cell antagonists and inhibitors atopic dermatitis immunology Anti-Inflammatory Agents Comorbidity Dermatitis, Atopic Humans Receptors, Interleukin-13 Receptors, Interleukin-4
Atopic dermatitis (AD) is a chronic inflammatory skin disease presenting with recurrent eczematous lesions and intense pruritus. It is common and affects both children and adults, often beginning in infancy. Due to the unpredictable disease course, its visible skin lesions, itching and scratching followed by sleeplessness, other associated atopic diseases, and behavioral and psychiatric disorders, AD is an immense burden for patients and caregivers. AD is determined by a genetic predisposition characterized by an impaired skin barrier and a T-helper-2-predominant inflammation. Restoration of the skin barrier is the main approach for treating and preventing AD. In order to cope with acute flares, usually topical corticosteroids (TCS) are applied, while topical calcineurin inhibitors (TCI) are used mainly for maintenance therapy. There is a small group of patients who are refractory to TCS and TCI and require systemic immunosuppressive drugs such as ciclosporin. Novel, targeted therapies